Tumori Journal Abstract Book - October 2020 - 160

160

Tumori Journal 106(2S)

glands cancers, 4 from nasopharyngeal cancer, 3 from thyroid, 2 from oral cavity and 1 from oropharyngeal cancer.
Median age of pts was 37 years (y), with range 27-43 y. In
10 pts (67%), HNC diagnosis occurred at a median gestational age of 28 weeks (range: 16-40 weeks). In other 5 pts
(33%), diagnosis was done post-partum with a median of 5
months (range: 1 week - 6 months). Stage distribution was
as follows: stage I (14% of pts), II (20%), III (26%), IV
(40%). Radiological staging was completed after childbirth in 80% of pts. Pregnancy outcome was an elective
childbirth in 3 pts and a therapeutic abortion in 1 case. In
the majority of pts (73%) delivery at term occurred. In
pregnant subjects, surgery of the primary tumor was performed in 3 pts, 2 pts with salivary glands cancer and one
with oral cavity cancer. Preterm delivery, congenital
anomalies of foetus and major maternal morbidities were
not observed. After childbirth, other 5 pts received surgery
(3 pts with thyroid cancer - of which 2 with metastatic disease - 2 pts with salivary gland cancer and one with oral
cancer), 8 pts received chemoradiation with curative (33%)
or postoperative intent, and 4 pts with metastatic disease
"ab initio" were treated with chemotherapy. The median
survival was 5.8 y (range: 15 months to 12 y). Seven pts
are still in complete remission at 6.5 y after diagnosis and
2 metastatic pts (salivary gland and thyroid carcinoma) are
alive at 10 y after diagnosis. Six pts died of disease; half of
them had salivary cancer.
Conclusions: All pts received state-of-the-art therapy
according to their clinical condition with encouraging long
term results suggesting that optimal treatment can be
safely delivered in women with HNC during pregnancy.

Material and Methods: We retrospectively evaluated a
series of 135 head and neck AdCC treated with curative
surgery at the Otolaryngology Head and Neck Surgery
Department of the University of Brescia, Italy, from 1997
to 2016 and we retrieved data from 41 pts who relapsed.
The following clinical and histological characteristics,
both at first treatment and at diagnosis of relapse, were
analysed and linked to overall survival (OS): gender, age,
pain, cranial nerve deficit, stage, grading (according to
Perzin), subsite of origin, biochemical analysis (neutrophil/lymphocytes, albumin), disease free interval (DFI),
site of relapse and site of metastasis.
Results: Relapsing patients were mainly female (59%),
with median age 55 years (21-83) and with primary disease in major (27%) or minor (73%) salivary gland.
Grading was scored as low, intermediate, high in 27%,
39%, and 34% of cases, respectively. 71% of patients had
undergone adjuvant radiotherapy after primary surgery.
Site of recurrence was local in 73%, regional in 12% and
distant in 39%; lung represented the most frequent site of
distant failure. Median disease free-interval (DFI) was 25
months (4-142). Only high grade (HR 5,1; 1,2-20,7; p=
0,021) was associated with worse 2-year OS since the
diagnosis of RM disease; on the contrary, patients with
DFI longer than 25 months had higher 2-year OS (HR
0,351; 0,157-0,786; p= 0,01)
Conclusions: Grading of disease at the time of first diagnosis and DFI are the main factors guiding prognosis after
relapse of AdCC. Given the paucity of clinical prognostic
data, we support extensive molecular analysis as next step
of research.

N07

N08

Clinical and histological
prognostic factors of recurrent
and/or metastatic salivary gland
adenoid cystic carcinoma

Gene expression profiling
to improve prognostic
characterization of olfactory
neuroblastoma and to define new
targetable pathways

Lorini L.1, Gurizzan C.1, Tomasoni M.1, Lombardi D.1, Mattavelli D.1,
Paderni A.1, Deganello A.1, Ardighieri L.1, Battocchio S.1, Bozzola A.1,
Ravanelli M.1, Maddalo M.1, Zamparini M.1, Magrini S.M.1, Maroldi
R.1, Nicolai P.2, Berruti A.1, Bossi P.1
1
Azienda Ospedaliera Spedali Civili di Brescia, Brescia; 2Azienda Ospedaliera
di Padova, Padova

Background: About 40% of radically treated adenoid
cystic carcinoma (AdCC) patients (pts) will recur locoregionally and up to 60% will develop distant metastasis.
Factors influencing the risk of recurrence have been studied, but very few data exist about prognostic factors in
recurrent/metastatic (RM) disease that could guide clinicians in the selection and tailoring of further treatments.
Main aim of the study is to evaluate patient, treatment and
disease characteristics impacting on survival for RM pts.

Romani C.1, Lorini L.1, Ravaggi A.1, Bignotti E.1, Paderno A.1,
Mattavelli D.1, Rampinelli V.1, Schreiber A.1, Ferrari M.1, Nicolai P.2,
Deganello A.1, Ravanelli M.1, Ardighieri L.1, Bozzola A.1, Battocchio
S.1, Castelnuovo P.3, Calza S.4, Magrini S.M.1, Turri Zanoni M.5,
Bossi P.1
1
Azienda Ospedaliera Spedali Civili di Brescia, Brescia; 2Azienda Ospedaliera
di Padova, Padova; 3Università dell'Insubria, Brescia; 4Università degli Studi di
Brescia, Brescia; 5Università dell'Insubria, Varese

Background: Olfactory neuroblastoma (ONB) is a rare neoplasm of sinonasal tract with a peculiar behaviour. Limited
prognostic factors are available, consisting in stage, grading
(according to Hyams' criteria) and Ki67 value. The project
aims at studying the pathways of ONB through gene expression analysis and correlating them with clinical outcome.

Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020